<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210303050559N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-03</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Nanofat in fine facial wrinkles</public_title>
      <acronym></acronym>
      <scientific_title>Investigation the effect of injection of nanofat for correction of fine facial wrinkles</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-03-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>15</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54744</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Other.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Facial wrinkles.</hc_freetext>
      <i_freetext>Intervention group: The effect of nano-fat injection in correcting fine facial wrinkles in patients over 40 years old with facial wrinkles referred to the skin department of Faghihi Hospital in Shiraz, any area with excess fat deposits is selected as a donor site. Surface injection of 2% lidocaine is performed with a 27G fine needle at the cannula entry points.Any area with excess fat deposits is selected as a donor site. Surface injection of 2% lidocaine is performed with a 27G fine needle at the cannula entry points. The infiltration cannula is a 3 mm diameter blunt-tipped device with many side openings attached to a 10 or 20 cc syringe. Fat (about 10 cc) after infiltration, mostly from the lower abdomen (or thigh) was removed with about 250 cc of swelling solution containing 1 mg of epinephrine 1:1000, 1000 cc of 0.9% normal saline and 25 ml of 2% lidocaine. will be The harvested fat is filtered through a sterile 0.5 mm pore size filter and then transferred between two 10 cc syringes connected to each other by a female-to-female luer-lok connector. After about 30 passes, the fat turns into an emulsion.At the end of the fragmentation process, the fat is liquefied and easily passes through the sharp needle (27G). The patient's face is anesthetized with topical lidocaine, and the processed fat is injected into the fine wrinkles. Patients are evaluated before, immediately after and 3 months after treatment. In each visit, we take pictures from the front, left and right with Visioface 1000D (Electronic CK, made in Germany). This device has the ability to measure volume, area and depth as three specified parameters of wrinkles that are quantitatively compared before and after treatment. Also, the side effects of fat grafting, such as erythema, edema, ecchymosis, and infection, will be explained to patients..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Because in my RCT, personal data is not important and doesnt change the outcome</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farzaneh akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dermatology clinic, Faghihi hospital, zand street, shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134846114</zip>
        <telephone>+98 71 3231 9049</telephone>
        <email>Farzane.akbarii@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farzane Akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dermatology clinic, faghihi hospital, zand street, shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134846114</zip>
        <telephone>+98 71 3231 9049</telephone>
        <email>Farzane.akbarii@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having fine facial wrinkles in forehead area</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having history of facial trauma
Co-morbidities
Botox injection 6 months before and 7 months after procedure
Previous operation for facial wrinkles
Filler injection for the facial wrinkles</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The effect of nano-fat injection in correcting fine facial wrinkles in patients over 40 years old with facial wrinkles referred to the skin department of Faghihi Hospital in Shiraz, any area with excess fat deposits is selected as a donor site. Surface injection of 2% lidocaine is performed with a 27G fine needle at the cannula entry points.Any area with excess fat deposits is selected as a donor site. Surface injection of 2% lidocaine is performed with a 27G fine needle at the cannula entry points. The infiltration cannula is a 3 mm diameter blunt-tipped device with many side openings attached to a 10 or 20 cc syringe. Fat (about 10 cc) after infiltration, mostly from the lower abdomen (or thigh) was removed with about 250 cc of swelling solution containing 1 mg of epinephrine 1:1000, 1000 cc of 0.9% normal saline and 25 ml of 2% lidocaine. will be The harvested fat is filtered through a sterile 0.5 mm pore size filter and then transferred between two 10 cc syringes connected to each other by a female-to-female luer-lok connector. After about 30 passes, the fat turns into an emulsion.At the end of the fragmentation process, the fat is liquefied and easily passes through the sharp needle (27G). The patient's face is anesthetized with topical lidocaine, and the processed fat is injected into the fine wrinkles. Patients are evaluated before, immediately after and 3 months after treatment. In each visit, we take pictures from the front, left and right with Visioface 1000D (Electronic CK, made in Germany). This device has the ability to measure volume, area and depth as three specified parameters of wrinkles that are quantitatively compared before and after treatment. Also, the side effects of fat grafting, such as erythema, edema, ecchymosis, and infection, will be explained to patients.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Depth of facial wrinkles. Timepoint: Before fat injection and 7 month later. Method of measurement: Using a device, visioface 1000D (ck electronic, manufactured in germany).</prim_outcome>
      <prim_outcome>Volume of facial wrinkle. Timepoint: Before fat injection and 7 month later. Method of measurement: Using a device, visioface 1000D (ck electronic, manufactured in germany).</prim_outcome>
      <prim_outcome>Area of facial wrinkle. Timepoint: Before fat injection and 7 month later. Method of measurement: Using a device, visioface 1000D (ck electronic, manufactured in germany).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Decreasing the depth of facial wrinkle. Timepoint: Before the fat injection and 7 month later. Method of measurement: Using a device, visioface 1000D ( ck electronic, manufactured in germany).</sec_outcome>
      <sec_outcome>Decreasing the volume of facial wrinkle. Timepoint: Before the fat injection and 7 month later. Method of measurement: Using a device, visioface 1000D ( ck electronic, manufactured in germany).</sec_outcome>
      <sec_outcome>Decreasing the area of facial wrinkle. Timepoint: Before the fat injection and 7 month later. Method of measurement: Using a device, visioface 1000D ( ck electronic, manufactured in germany).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-04-22</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>University of medical science, zand street, shiraz shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
